CliffBio
biologic

Flublok

Influenza Vaccine

Loss of exclusivityJanuary 2025FDA regulatory exclusivity expiry
CompanyProtein Sciences Corporation →See this company's full patent-cliff portfolio

Drug detail

Brand nameFlublok
Active ingredientInfluenza Vaccine
Strength135UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 2013
Marketing statusRx

More from Protein Sciences Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Flublok patent cliff — loss of exclusivity January 2025 | CliffBio